Literature DB >> 29686831

Microarray Analysis of the Molecular Mechanism Involved in Parkinson's Disease.

Cheng Tan1, Xiaoyang Liu1, Jiajun Chen1.   

Abstract

PURPOSE: This study aimed to investigate the underlying molecular mechanisms of Parkinson's disease (PD) by bioinformatics.
METHODS: Using the microarray dataset GSE72267 from the Gene Expression Omnibus database, which included 40 blood samples from PD patients and 19 matched controls, differentially expressed genes (DEGs) were identified after data preprocessing, followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Protein-protein interaction (PPI) network, microRNA- (miRNA-) target regulatory network, and transcription factor- (TF-) target regulatory networks were constructed.
RESULTS: Of 819 DEGs obtained, 359 were upregulated and 460 were downregulated. Two GO terms, "rRNA processing" and "cytoplasm," and two KEGG pathways, "metabolic pathways" and "TNF signaling pathway," played roles in PD development. Intercellular adhesion molecule 1 (ICAM1) was the hub node in the PPI network; hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b participated in PD pathogenesis. Six TFs, including zinc finger and BTB domain-containing 7A, ovo-like transcriptional repressor 1, GATA-binding protein 3, transcription factor dp-1, SMAD family member 1, and quiescin sulfhydryl oxidase 1, were related to PD.
CONCLUSIONS: "rRNA processing," "cytoplasm," "metabolic pathways," and "TNF signaling pathway" were key pathways involved in PD. ICAM1, hsa-miR-7-5p, hsa-miR-433-3p, hsa-miR-133b, and the abovementioned six TFs might play important roles in PD development.

Entities:  

Year:  2018        PMID: 29686831      PMCID: PMC5852864          DOI: 10.1155/2018/1590465

Source DB:  PubMed          Journal:  Parkinsons Dis        ISSN: 2042-0080


1. Introduction

Parkinson's disease (PD) is one of the most common age-related neurodegenerative diseases [1]. The age at PD onset is approximately 55 years, and the incidence in the population aged > 65 years is approximately 1% [1-3]. PD mainly occurs because of the death of dopaminergic neurons in the substantia nigra [4]. Patients with PD present with symptoms such as bradykinesia, resting tremor, rigidity, and postural instability [5]. The current therapy for PD is targeted at its symptoms rather than at dopaminergic neuron degeneration [1]. The diagnosis of PD at the early stage is challenging, and successfully managing PD is difficult at its later stages [4]. To date, the cause of PD remains unknown; however, it appears to involve the intricate interplay of environmental and genetic factors [1, 4]. Much effort has been spent in investigating PD pathogenesis, and the misfolding, aggregation, and aberrance of proteins are considered to be some of the main causes [1, 4, 5]. Some key genes such as hydrogen sulfide, chromobox 5 (CBX5), and transcription factor 3 (TCF3) are related to PD [6, 7]. Several pathways have also been identified to be related to PD. Activation of the protein kinase B (Akt)/glycogen synthase kinase 3 beta/(GSK3β) pathway by urate reportedly protects dopaminergic neurons in a rat model of PD [8]. In addition, the E2-related factor 2 (Nrf2)/antioxidant response element pathway reportedly counteracts mitochondrial dysfunction, which is a prominent PD feature [9]. The ubiquitin, lipid, nigrostriatal, autophagy-lysosome, and endosomal pathways are also involved in PD [10-15]. Furthermore, a recent study revealed several microRNAs (miRNAs) associated with PD; miR-205 suppresses LRRK2 expression and miR-205 expression levels in the brains of patients with PD decreases [16]. Furthermore, miR-34b and miR-34c are downregulated in the brains of patients with PD, which is related to the reduction in the expression of DJ-1 and PARKIN [17], and miR-133 and miR-7 are also associated with PD [18-20]. Numerous reports that have described the roles of transcription factors (TFs) in PD have also been published. The TF paired-like homeodomain 3 has roles in developing and maintaining dopaminergic neurons [21, 22], and engrailed l, which is downregulated in the rat models, plays a role in the apoptosis of dopaminergic neurons and the symptoms of PD [23]. Moreover, Nrf2, nuclear factor kappa B (NF-κB), GATA2, and PHD finger protein 10 are TFs involved in PD [24-27]. However, understanding the key mechanisms underlying the development of PD remains unclear. In a previous study, the microarray dataset GSE72267 generated by Calligaris et al. [7] was used to identify key differentially expressed genes (DEGs) such as CBX5, TCF3, dedicator of cytokinesis 10, and mannosidase alpha class 1C in the blood of patients with PD compared with those of healthy controls. Moreover, crucial pathways related to chromatin remodeling and methylation were revealed. In the current study, we downloaded this microarray dataset to comprehensively analyze DEGs in patients with PD compared with those in matched controls by bioinformatics approaches and to describe their functional annotations. Compared with the previous analysis conducted by Calligaris et al. [7], we performed additional analyses, including those for the protein-protein interaction (PPI), miRNA-target regulatory, and TF-target regulatory networks, to further elucidate the key mechanisms underlying PD. Our results may provide useful data for diagnosing and treating PD.

2. Materials and Methods

2.1. Affymetrix Microarray Data

Gene expression profile data GSE72267 was extracted from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/) [28]. The GSE72267 dataset was deposited by Calligaris et al. [7], including blood samples from 40 PD patients and 19 healthy matched controls and was based on the platform of the GPL571 (HG-U133A-2) Affymetrix Human Genome U133A 2.0 Array (Affymetrix Inc., Santa Clara, California, USA). This dataset was downloaded and analyzed on October 2016.

2.2. Data Preprocessing and DEG Screening

The downloaded data in CEL files were preprocessed using the Affy package (version 1.50.0) [29] in R language, including background correction, normalization, and expression calculation. Annotations to the probes were performed, and probes that were not matched to the gene symbol were excluded. The average expression values were taken if different probes mapped to the same gene. DEGs in patients with PD compared with those in healthy matched controls were analyzed using the limma package (version 3.10.3) [30] in R language. The cutoff threshold was set to a p value of <0.05.

2.3. Pathway Enrichment Analysis

Gene ontology (GO) (http://www.geneontology.org/) analysis is commonly used for functional studies of large-scale genomic or transcriptomic data and classifies functions with respect to three aspects: molecular function (MF), cellular component (CC), and biological process (BP) [31, 32]. The Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.kegg.jp/) pathway database [33] is widely used for systematic analysis of gene functions, linking genomic data with higher order functional data. The database for annotation, visualization, and integrated discovery (DAVID) is an integrated biological knowledgebase with analytical tools used for systematic and integrative analysis of large gene lists [34]. In this study, GO terms and KEGG pathway enrichment analyses for up- and downregulated DEGs were performed using DAVID (version 6.8). The cutoff thresholds were as follows: an enrichment gene number count of ≥2 and a super geometry inspection significance threshold p value of <0.05.

2.4. PPI Network Analysis

Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; http://www.string-db.org/) [35] is an online database that assesses and integrates PPIs. In this study, DEGs were mapped into the STRING database for PPI analysis, with a PPI score of 0.4 as the parameter setting. The PPI network established by DEGs was constructed using the Cytoscape software (version 3.2.0) [36], and the topology scores of the nodes, including node degree in the PPI network, were analyzed using the CytoNCA plugin (version 2.1.6; http://apps.cytoscape.org/apps/cytonca) [37] (parameter setting: without weight). Degree was used for describing importance of protein nodes in network. The higher the degree was, the more important the nodes were in network. In addition, subnetworks were identified using the MCODE plugin [38] in the Cytoscape software, and subnetworks with a score of >5 were identified as key subnetworks. Finally, KEGG pathway enrichment analyses for the genes in the key subnetworks were performed.

2.5. miRNA-Target Regulatory Network Analysis

The miR2disease (http://www.mir2disease.org/) database [39] is a manually curated database that provides a comprehensive resource of miRNA deregulation in various human diseases. miRWalk2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/) [40] is a comprehensive database that presents predicted and validated data, regarding miRNA targets in human, mouse, and rats. In this study, miRNAs related to PD were extracted from the miR2disease database, and experimentally verified miRNA-gene regulatory pairs were obtained by searching miRWalk2.0. Finally, a miRNA-target regulatory network was constructed by comparing DEGs with obtained miRNA-gene regulatory pairs using the Cytoscape software.

2.6. TF-Target Regulatory Network Analysis

The genes in the PPI network described above were further analyzed to identify TF-target interaction pairs that were then used to construct a TF-target regulatory network. The iRegulon plugin (version 1.3; http://apps.cytoscape.org/apps/iRegulon) [41] in the Cytoscape software collects multiple human TF-target interaction databases such as Transfac, Jaspar, and Encode using two computational methods: Motif and Track. In this study, we analyzed the TF-target pairs using the iRegulon plugin and compared them with TFs with DEGs in the PPI network, followed by a TF-target regulatory network construction. The parameter settings were as follows: minimum identity between orthologous genes, 0.05 and maximum false discovery rate on motif similarity, 0.001. The normalized enrichment score (NES) indicates the reliability of the results, and the cutoff threshold was NES of >3.

3. Results

3.1. Analysis of DEGs

The boxplot of the preprocessed data indicated good normalization (Figure 1). In total, 22,277 probes were obtained, among which 971 probes were differentially expressed. After annotation, 819 DEGs in patients with PD compared with those in healthy matched controls were identified (Supplementary Table 1), including 359 upregulated DEGs and 460 downregulated DEGs.
Figure 1

Boxplots for normalized gene expression data. Red represents the blood samples of patients with Parkinson's disease, and white represents the healthy matched control samples.

3.2. Pathway Enrichment Analysis

GO and KEGG pathway enrichment analyses for the up- and downregulated DEGs were performed (Supplementary Table 2). The significant GO terms and KEGG pathways are shown in Figure 2. The upregulated DEGs were significantly enriched in four KEGG pathways, namely, metabolic pathways, inositol phosphate metabolism, mRNA surveillance pathway, and RNA degradation, and GO terms such as transcription, DNA-template processing, and rRNA processing (Figure 2). The downregulated DEGs were enriched in pathways such as those of influenza A, viral myocarditis, and TNF signaling and GO terms such as cytoplasm, cell surface, and interferon gamma-mediated signaling pathway (Figure 2).
Figure 2

Functional enrichment analyses of differentially expressed genes (DEGs). (a) Gene Ontology (GO) terms and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways of upregulated DEGs and (b) GO terms and KEGG pathways of downregulated DEGs. The numbers on the x-axis were the ID of pathways or GO terms. The numbers on the y-axis were gene counts.

3.3. PPI Network Analysis

The PPI network, including 605 nodes and 1937 PPI pairs, is shown in Figure 3. The top 10 DEGs with the highest degree included five upregulated DEGs such as estrogen receptor 1 (ESR1), mechanistic target of rapamycin (MTOR), ATM serine/threonine kinase (ATM), CD40 molecule (CD40) and thymidine kinase 2, mitochondrial (TK2), and five downregulated DEGs such as mitogen-activated protein kinase 14 (MAPK14), phosphatase and tensin homolog (PTEN), intercellular adhesion molecule 1 (ICAM1), aurora kinase A (AURKA), and protein kinase, DNA-activated, catalytic polypeptide (PRKDC) (Table 1). Three subnetworks were identified (subnetworks a–c). Subnetwork a (Figure 4) included nine nodes and 36 PPI pairs, and these genes were significantly enriched in three KEGG pathways (Table 2), including neuroactive ligand-receptor interaction, chemokine signaling pathway, and cytokine-cytokine receptor interaction. Subnetwork b (Figure 4) included seven nodes and 21 PPI pairs, and these genes were not enriched in any KEGG pathway. Subnetwork c (Figure 4) included 27 nodes and 81 PPI pairs, and these genes were enriched in 12 KEGG pathways (Table 2), such as cell cycle, herpes simplex infection, and NF-κB signaling pathways. In addition, ICAM1 was involved in six KEGG pathways of subnetwork c, such as viral myocarditis, cell adhesion molecules (CAMs), and NF-κB signaling pathways (Table 2). The detailed information existed in PPI network, and three subnetworks are shown in Supplementary Table 3.
Figure 3

The protein-protein interaction (PPI) network of differentially expressed genes (DEGs). Red circles represent upregulated DEGs, and green diamonds represent downregulated DEGs.

Table 1

List of top 10 differentially expressed genes with higher degrees in protein-protein interaction network.

GeneFull nameDescriptionDegree
MAPK14Mitogen-activated protein kinase 14Down68
ESR1Estrogen receptor 1Up54
PTENPhosphatase and tensin homologDown52
MTORMechanistic target of rapamycinUp40
ATMATM serine/threonine kinaseUp35
ICAM1Intercellular adhesion molecule 1Down33
CD40CD40 moleculeUp32
AURKAAurora kinase ADown31
PRKDCProtein kinase, DNA-activated, catalytic polypeptideDown29
TK2Thymidine kinase 2, mitochondrialUp29

Degree was used for describing the importance of protein nodes in network. The higher the degree was, the more important the nodes were in network.

Figure 4

Subnetworks of differentially expressed genes (DEGs). (a) Subnetwork a; (b) subnetwork b; (c) subnetwork c. Red circles represent upregulated DEGs, and green diamonds represent downregulated DEGs.

Table 2

List of KEGG pathways of subnetworks.

SubnetworkPathway IDPathway nameCount p valueGenes
Subnetwork ahsa04080Neuroactive ligand-receptor interaction51.40E−04MCHR1, PTGER3, S1PR5, FPR3, NPY1R
hsa04062Chemokine signaling pathway31.80E−02CCR9, CCR6, CCR4
hsa04060Cytokine-cytokine receptor interaction32.74E−02CCR9, CCR6, CCR4
Subnetwork chsa04110Cell cycle61.31E−04CCNB1, CDC14A, PRKDC, CCNA2, MCM4, TFDP1
hsa05416Viral myocarditis41.62E−03ICAM1, CASP8, HLA-C, CD40
hsa05168Herpes simplex infection56.03E−03SP100, CASP8, OAS3, PML, HLA-C
hsa04514Cell adhesion molecules41.70E−02VCAM1, ICAM1, HLA-C, CD40
hsa05144Malaria31.78E−02VCAM1, ICAM1, CD40
hsa04621NOD-like receptor signaling pathway32.00E−02CASP8, RIPK2, CASP1
hsa04115p53 signaling pathway32.93E−02CCNB1, RRM2, CASP8
hsa05164Influenza A43.32E−02ICAM1, OAS3, PML, CASP1
hsa04914Progesterone-mediated oocyte maturation34.30E−02CCNB1, GNAI2, CCNA2
hsa05169Epstein–Barr virus infection44.42E−02ICAM1, HLA-C, CD40, CCNA2
hsa05203Viral carcinogenesis44.60E−02SP100, CASP8, HLA-C, CCNA2
hsa04064NF-kappa B signaling pathway34.84E−02VCAM1, ICAM1, CD40

KEGG, Kyoto Encyclopedia of Genes and Genomes.

3.4. miRNA-Target Regulatory Network Analysis

According to the data from the miR2disease database, six miRNAs were identified to be associated with PD and 698 miRNA-gene pairs were obtained by searching miRWalk2.0. A total of 40 miRNA-target interaction pairs were obtained by comparing miRNA-gene pairs with DEGs, and subsequently, the miRNA-target regulatory network was constructed. The network (Figure 5) contained 40 miRNA-target interaction pairs and 43 nodes (Supplementary Table 4), among which three miRNAs (hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b) were included.
Figure 5

MicroRNA- (miRNA-) target regulatory networks of differentially expressed genes (DEGs). Triangles represent miRNAs, red circles represent upregulated DEGs, and green diamonds represent downregulated DEGs.

3.5. TF-Target Regulatory Network Analysis

According the information of TF-target interaction databases such as Transfac, Jaspar, and Encode in the Cytoscape software, a total of 83 TFs were identified from the PPI network, forming 5371 TF-gene pairs. Among the 83 TFs, six were differentially expressed: three upregulated ones, that is, zinc finger and BTB domain-containing 7A (ZBTB7A), ovo-like transcriptional repressor 1 (OVOL1), and GATA-binding protein 3, and three downregulated ones, that is, transcription factor dp-1 (TFDP1), SMAD family member 1 (SMAD1), and quiescin sulfhydryl oxidase 1 (QSOX1). The TF-target regulatory network (Figure 6) was constructed and included 166 nodes and 288 interaction pairs (Supplementary Table 5). The top 20 nodes with the highest degree are listed in Table 3, including the six TFs described above and 14 other DEGs, such as ectodermal-neural cortex 1, fibronectin type III domain-containing 3A, and midline 1, which were coregulated by the six TFs.
Figure 6

The TF-target regulatory network of differentially expressed genes (DEGs). Blue boxed figures represent TFs, red circles represent upregulated genes, and green diamonds represent downregulated genes. TF, transcription factor.

Table 3

List of top 20 nodes with higher degree in transcription factor-target regulatory network.

GeneFull nameDescriptionDegree
TFDP1 Transcription factor Dp-1Down62
ZBTB7A Zinc finger and BTB domain-containing 7AUp55
OVOL1 Ovo-like transcriptional repressor 1Up46
SMAD1 SMAD family member 1Down45
QSOX1 Quiescin sulfhydryl oxidase 1Down44
GATA3 GATA-binding protein 3Up38
ENC1Ectodermal-neural cortex 1Down6
FNDC3AFibronectin type III domain-containing 3AUp6
MID1Midline 1Down6
PDE4DPhosphodiesterase 4DDown5
ZNF362Zinc finger protein 362Up5
CBLBCbl proto-oncogene BDown4
LARGELARGE xylosyl- and glucuronyltransferaseUp4
TRPC4Transient receptor potential cation channel subfamily C member 4Down4
CTBP2C-terminal binding protein 2Up4
GLI3GLI family zinc finger 3Down4
SCN3ASodium voltage-gated channel alpha subunit 3Up4
TAL1TAL BHLH transcription factor 1, erythroid differentiation factorDown4
LRRN3Leucine rich repeat neuronal 3Up3
MAST4Microtubule-associated serine/threonine kinase family member 4Up3

∗Transcription factor.

4. Discussion

PD is the second most common age-related neurodegenerative disease. However, the pathogenesis and genes involved in PD are not well known [42]. In this study, we performed a comprehensive bioinformatics analysis of the blood gene expression profile using the GSE72267 dataset. The results suggested that four key pathways (metabolic pathways, TNF signaling pathway, rRNA processing, and cytoplasm), the key gene ICAM1, three miRNAs (hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b), and six TFs (ZBTB7A, OVOL1, GATA3, TFDP1, SMAD1, and QSOX) might play important roles in PD development. Our results revealed that the upregulated DEGs were enriched in the KEGG pathway “metabolic pathways” and the GO term “rRNA processing,” and the downregulated DEGs were enriched in the KEGG pathway “TNF signaling pathway” and the GO term “cytoplasm.” A previous study [43] demonstrated that some metabolic patterns were altered in patients with advanced PD. Multiple metabolic pathways are also involved in PD [44], which supports our study results. Cytoplasmic inclusions are a pathological hallmark of PD [45]. Lewy body pathology is involved [46, 47], and glial cytoplasmic inclusions are associated with Lewy bodies [48]. Thus, the GO term “cytoplasm” may play a role in PD. Furthermore, TNF receptor-associated protein is excluded from the nucleolus and is sequestered to the cytoplasm by TNF receptor-associated factor 6, thereby altering ribosomal RNA (rRNA) biogenesis [49]. The TNF signaling pathway is also involved in PD [50], and rRNA transcription is repressed in patients with PD [51]. Therefore, the GO term “rRNA processing” and the KEGG pathway “TNF signaling pathway” may play important roles in PD. Altogether, the metabolic pathways, TNF signaling pathway, rRNA processing, and cytoplasm are essentially involved in PD pathogenesis. ICAM1 was among the top 10 DEGs in the PPI network. Moreover, ICAM1 gene was involved in six KEGG pathways for subnetwork c. ICAM1 is involved in the adhesion and transmigration of leukocytes across the endothelium, promoting brain inflammation and resulting in brain diseases [52]. T helper 17 cells can exert a neurotoxic effect in the brain parenchyma of patients with PD by interacting with ICAM1 and leukocyte function-associated antigen 1 [53]. In addition, ICAM1 is involved in persistent inflammation in PD [54]. Our results from the KEGG pathway analysis for genes in subnetworks revealed that ICAM1 might play roles in viral myocarditis and CAMs and thus contributed to PD. The miRNA-target regulatory network analysis identified three miRNAs involved in PD, namely, hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b. A study described miR-7-2 dysregulation (the stem loop of hsa-miR-7-5p) in Parkinson's patient's leukocytes [55] and revealed that hsa-miR-7-5p expression decreased in PD, possibly upregulating α-SYN, a PD-related gene [56]. The variation of the hsa-miR-433- (the stem loop of hsa-miR-433-3p-) binding site of fibroblast growth factor 20 can lead to α-SYN overexpression, increasing the risk for PD [57]. hsa-miR-133b expression is increased in the cerebrospinal fluid of patients with PD [58]; however, its expression levels in serum is decreased, which is related to low serum ceruloplasmin levels [59]. hsa-miR-133b is also deficient in the midbrain tissue of patients with PD and is associated with the maturation and function of midbrain dopaminergic neurons [60]. Notably, reduced circulating levels of miR-433 and miR-133b are considered as promising biomarkers for PD [61]. Therefore, we speculate that the three miRNAs, including hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b may play important roles in PD. TFs are important regulators of target gene expressions [53, 62]. In this study, we analyzed DEGs in the PPI network to screen TFs involved in PD. Among the 83 TFs identified in the PPI network, six were found to be differentially expressed. ZBTB7A, OVOL1, and GATA3 were upregulated in patients with PD compared with those in healthy matched controls, whereas TFDP1, SMAD1, and QSOX1 were downregulated. ZBTB7A is a tumor suppressor, which is involved in several cancers such as prostate and nonsmall cell lung cancers [63-65]. OVOL1, encoding a zinc finger protein, is expressed in embryonic epidermal progenitor cells and is an inducer of mesenchymal-to-epithelial transition in human cancers [66, 67]. GATA3, a member of the GATA family, is a regulator of T-cell development and plays roles in endothelial cells [68, 69]. TFDP1 is involved in the cell cycle and contributes to hepatocellular carcinomas [70, 71], SMAD1 is involved in multiple pathways [72, 73], and QSOX1 plays roles in some cancers such as breast cancer and neuroblastoma [74-76]. However, there are few reports regarding the involvement of these TFs in PD. Hence, further studies regarding the associations between the TFs identified in this study and PD are warranted. In conclusion, our data demonstrated that the metabolic pathways, TNF signaling pathway, rRNA processing, and cytoplasm play important roles in PD pathogenesis; ICAM1 might also play a vital role. Besides six TFs, three miRNAs, including hsa-miR-7-5p, hsa-miR-433-3p, and hsa-miR-133b, may be involved in PD. However, because of the study limitations, further investigation remains to be performed in the future.
  70 in total

1.  KEGG: kyoto encyclopedia of genes and genomes.

Authors:  M Kanehisa; S Goto
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal.

Authors:  Luis C Fuentealba; Edward Eivers; Atsushi Ikeda; Cecilia Hurtado; Hiroki Kuroda; Edgar M Pera; Edward M De Robertis
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

3.  CytoNCA: a cytoscape plugin for centrality analysis and evaluation of protein interaction networks.

Authors:  Yu Tang; Min Li; Jianxin Wang; Yi Pan; Fang-Xiang Wu
Journal:  Biosystems       Date:  2014-11-15       Impact factor: 1.973

4.  Association of Lewy bodies and glial cytoplasmic inclusions in the brain of Parkinson's disease.

Authors:  Akihide Mochizuki; Yasuko Komatsuzaki; Shin'ichi Shoji
Journal:  Acta Neuropathol       Date:  2002-06-27       Impact factor: 17.088

5.  A MicroRNA feedback circuit in midbrain dopamine neurons.

Authors:  Jongpil Kim; Keiichi Inoue; Jennifer Ishii; William B Vanti; Sergey V Voronov; Elizabeth Murchison; Gregory Hannon; Asa Abeliovich
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

6.  Transcription factor PITX3 gene in Parkinson's disease.

Authors:  Weidong Le; Deanne Nguyen; Xiyao Wendy Lin; Pawan Rawal; Maosheng Huang; Yujian Ding; Wenjie Xie; Hao Deng; Joseph Jankovic
Journal:  Neurobiol Aging       Date:  2009-04-24       Impact factor: 4.673

7.  Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease.

Authors:  Na Zhao; Lirong Jin; Guoqiang Fei; Zhiyong Zheng; Chunjiu Zhong
Journal:  Parkinsonism Relat Disord       Date:  2014-09-01       Impact factor: 4.891

8.  Gene amplification is a relatively frequent event leading to ZBTB7A (Pokemon) overexpression in non-small cell lung cancer.

Authors:  K Apostolopoulou; I S Pateras; K Evangelou; P K Tsantoulis; M Liontos; C Kittas; D G Tiniakos; A Kotsinas; C Cordon-Cardo; V G Gorgoulis
Journal:  J Pathol       Date:  2007-11       Impact factor: 7.996

9.  Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6.

Authors:  Sandra Vilotti; Marta Codrich; Marco Dal Ferro; Milena Pinto; Isidro Ferrer; Licio Collavin; Stefano Gustincich; Silvia Zucchelli
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

10.  ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis.

Authors:  Xue-Song Liu; Jenna E Haines; Elie K Mehanna; Matthew D Genet; Issam Ben-Sahra; John M Asara; Brendan D Manning; Zhi-Min Yuan
Journal:  Genes Dev       Date:  2014-09-01       Impact factor: 11.361

View more
  6 in total

1.  Transcriptome Analysis Reveals Distinct Responses to Physiologic versus Toxic Manganese Exposure in Human Neuroblastoma Cells.

Authors:  Jolyn Fernandes; Joshua D Chandler; Loukia N Lili; Karan Uppal; Xin Hu; Li Hao; Young-Mi Go; Dean P Jones
Journal:  Front Genet       Date:  2019-07-24       Impact factor: 4.599

2.  Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study.

Authors:  Sid E O'Bryant; Melissa Edwards; Fan Zhang; Leigh A Johnson; James Hall; Yuliya Kuras; Clemens R Scherzer
Journal:  Alzheimers Dement (Amst)       Date:  2019-05-02

3.  Protein Deimination Signatures in Plasma and Plasma-EVs and Protein Deimination in the Brain Vasculature in a Rat Model of Pre-Motor Parkinson's Disease.

Authors:  Marco Sancandi; Pinar Uysal-Onganer; Igor Kraev; Audrey Mercer; Sigrun Lange
Journal:  Int J Mol Sci       Date:  2020-04-15       Impact factor: 5.923

4.  Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinson's disease patients.

Authors:  Zerrin Karaaslan; Özlem Timirci Kahraman; Elif Şanlı; Hayriye Arzu Ergen; Canan Ulusoy; Başar Bilgiç; Vuslat Yılmaz; Erdem Tüzün; Haşmet Ayhan Hanağası; Cem İsmail Küçükali
Journal:  Sci Rep       Date:  2021-01-27       Impact factor: 4.379

5.  Identification of Potential Core Genes in Parkinson's Disease Using Bioinformatics Analysis.

Authors:  Wei Quan; Jia Li; Xiya Jin; Li Liu; Qinghui Zhang; Yidan Qin; Xiaochen Pei; Jiajun Chen
Journal:  Parkinsons Dis       Date:  2021-09-17

6.  Single-cell transcriptomics of human iPSC differentiation dynamics reveal a core molecular network of Parkinson's disease.

Authors:  Gabriela Novak; Dimitrios Kyriakis; Kamil Grzyb; Michela Bernini; Sophie Rodius; Gunnar Dittmar; Steven Finkbeiner; Alexander Skupin
Journal:  Commun Biol       Date:  2022-01-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.